ClinicalTrials.gg
RecruitingNCT07323368ARTS-PIVOTUpdated Feb 10, 2026

Advancing Reperfusion Therapy for Ischemic Stroke: Perfusion-guided Endovascular Intervention for Medium Vessel Occlusion Therapy

An interventional study of Endovascular treatment and Best medical treatment (BMT) in Stroke Ischemic and Medium Vessel Occlusions, sponsored by Beijing Tiantan Hospital. Recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
568
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 86 studies in Ischemic Stroke by Beijing Tiantan Hospital — 46 open to participants now, 47 under way, 15 of them phase 3. Ischemic Stroke · Beijing Tiantan Hospital.

Planned enrollment
37th of 77
568 · median 564
Started
2026
with 18 others
No phase
31 of 86
15 open now
Primary completion
2027-09
later than 29 of 46 live
Registered
69th of 86
by date

Among the 86 studies in Ischemic Stroke by Beijing Tiantan Hospital, this one is the 37th largest by planned enrollment of the 77 interventional ones that give a count, is one of 19 that started in 2026, is one of 31 with no phase, reaches primary completion later than 29 of the 46 other live ones, and was the 69th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

46 of the 86 studies in Ischemic Stroke by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

40 more — sign in →

By country, each count listing its studies:

All 46 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Ischemic Stroke by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

The investigators initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of perfusion-guided endovascular treatment (EVT) compared to standard medical care for patients with acute ischemic stroke due to medium vessel occlusion (MeVO) within 24 hours from symptom onset.

Read the detailed description

Adult acute ischemic stroke patients due to primary medium vessel occlusions (non-dominant proximal M2 or mid-distal M2/M3 segments of the middle cerebral artery, A1/A2/A3 segments of the anterior cerebral artery, and P1/P2/P3 segments of the posterior cerebral artery) confirmed by CTA/MRA and responsible for the signs and symptoms of acute ischemic stroke with baseline National Institutes of Health Stroke Scale (NIHSS) ≥8 will be enrolled in this trial. The investigators use perfusion imaging to select subjects and the enrolled patients have target mismatch profile on CTP or MRI+PWI (ischemic core volume \<70mL, mismatch ratio>1.2, mismatch volume >10mL). The eligible patients will be randomly assigned to receive endovascular treatment (EVT) +best medical treatment or best medical treatment within 24 hours after the time that the patient was last known to be well (including after stroke on awakening and unwitnessed stroke). The primary outcome is the proportion of patients with an mRS score ≤ 1 at 90 days.

03

Conditions studied

  • Stroke Ischemic
  • Medium Vessel Occlusions

Browse trials for

Keywords

  • ischemic stroke
  • medium vessel occlusions
  • endovascular treatment
  • perfusion imaging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age≥18 years old;
  • Acute ischemic stroke symptom onset within 24 hours; including wake-up stroke and unwitnessed stroke, onset time refers to "last-seen normal time";
  • Primary medium vessel occlusions confirmed by CTA/MRA, including non-dominant proximal M2 or mid-distal M2/M3 segments of the middle cerebral artery (MCA), A1/A2/A3 segments of the anterior cerebral artery (ACA), and P1/P2/P3 segments of the posterior cerebral artery (PCA) and responsible for the signs and symptoms of acute ischemic stroke;
  • Pre-stroke modified Rankin scale (mRS) score ≤1;
  • Baseline National Institutes of Health Stroke Scale (NIHSS) ≥8;
  • Neuroimaging criteria: Target mismatch profile on CT perfusion or MRI+MR perfusion (ischemic core volume \<70 mL, mismatch rate >1.2, mismatch volume >10 mL);
  • Written from patients or their legally authorized representatives.

Exclusion criteria

Exclusion Criteria:

  • Any evidence of intracranial hemorrhage on qualifying imaging;
  • Known (serious) sensitivity to radiographic contrast agents, nickel, titanium metals or their alloys and unable to complete CTP/PWI;
  • Known history of arterial tortuosity, pre-existing stent, other arterial disease and/or known disease at the arterial access site that would prevent the device from reaching the target vessel and/or preclude safe recovery after EVT;
  • Radiological confirmed evidence of mass effect or intracranial tumour (except small meningioma);
  • Clinical diagnosis of cerebral vasculitis;
  • Evidence of vessel recanalization prior to randomisation;
  • Severe comorbidities, which will likely prevent improvement or follow-up;
  • Any terminal illness such that the patient would not be expected to survive more than 1 year;
  • Hypodensity in >1/3 MCA territory on non-contrast CT or significant hypodensity outside the current perfusion lesion suggesting distal clot migration (secondary MeVO);
  • Multiple arterial occlusion;
  • Pregnant women, nursing mothers, or reluctance to use effective measures during the period of the trial;
  • Unlikely to adhere to the trial protocol or follow-up;
  • Participation in other interventional clinical trials within the previous 3 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
568 participants (estimated)

Study arms

  • Experimental
    Endovascular treatment (EVT) +Best medical treatment

    The treating physician should attempt to perform EVT with the goal to restore blood flow to the affected vascular territory immediately after randomisation. EVT included thrombectomy with stent retrievers, thromboaspiration, intraarterial thrombolysis, balloon angioplasty, stenting, or a combination of these approaches at the discretion of the interventional team. All decisions regarding the performance of EVT are made by the treating physician, based on his/her own judgement, and using local standards for endovascular treatment technique and devices and/or medications used for EVT. All other treatments (especially after-care and best medical treatment) will not differ between the intervention and control group.

    Procedure: Endovascular treatment

  • Other
    Best medical treatment (BMT)

    Administration of BMT should be done according to routine clinical practice and current guidelines.

    Drug: Best medical treatment (BMT)

Interventions

  • ProcedureEndovascular treatment

    EVT included thrombectomy with stent retrievers, thromboaspiration, intraarterial thrombolysis, balloon angioplasty, stenting, or a combination of these approaches at the discretion of the interventional team.

  • DrugBest medical treatment (BMT)

    Administration of BMT should be done according to routine clinical practice and current international guidelines. Administration of BMT must not be delayed by randomisation and should be done independently from participation in this trial.

06

What researchers measure

Primary outcomes

  1. The proportion of patients who have a score of 0 or 1 on the modified Rankin Scale (mRS) at 90 days

    The proportion of patients with an mRS score ≤ 1 at 90 days. The mRS score is a seven-point ordered categorical scale from 0 to 6 for functional neurological outcome, with 0 indicating no neurological symptoms and 6 indicating death.

    Time frame: 90 days

Secondary outcomes

  1. Ordinal distribution of modified Rankin Scale (mRS) at 90 days

    Ordinal distribution of mRS at 90 days (shift analysis). The mRS score is a seven-point ordered categorical scale from 0 to 6 for functional neurological outcome, with 0 indicating no neurological symptoms and 6 indicating death.

    Time frame: 90 days

  2. The proportion of patients with an modified Rankin Scale (mRS) score of 0-2 at 90 days

    The proportion of patients with an mRS score of 0-2 at 90 days. The mRS score is a seven-point ordered categorical scale from 0 to 6 for functional neurological outcome, with 0 indicating no neurological symptoms and 6 indicating death.

    Time frame: 90 days

  3. The rate of early neurological improvement at 24 hours

    The rate of early neurological improvement at 24 hours after randomization (defined as a National Institute of Health Stroke Scale \[NIHSS\] score ≤1 or ≥4 points compared with the baseline)

    Time frame: 24 hours

  4. The proportion of patients with an modified Rankin Scale (mRS) score of 5-6 at 90 days

    The proportion of patients with an mRS score of 0-2 at 90 days. The mRS score is a seven-point ordered categorical scale from 0 to 6 for functional neurological outcome, with 0 indicating no neurological symptoms and 6 indicating death.

    Time frame: 90 days

  5. The median value of EuroQol 5-Dimension (EQ-5D) index

    EuroQol 5-Dimension (EQ-5D) index at 90 days and 1 year. The EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D) is a standardized instrument for the measurement of health status. The domains mobility, self-care, everyday activity, pain or physical discomfort, and fear or depression are assessed on a five-point scale, with 1 indicating no problem in this domain and 3 indicating extreme problems. The visual analogue scale ranges from 0 to 100, with 0 indicating the worst health imaginable and 100 the best health imaginable.

    Time frame: 90 days and 1 year

  6. Ordinal distribution of modified Rankin Scale (mRS) at 1 year

    Ordinal distribution of modified Rankin Scale (mRS) at 90 days. The mRS score is a seven-point ordered categorical scale from 0 to 6 for functional neurological outcome, with 0 indicating no neurological symptoms and 6 indicating death.

    Time frame: 1 year

  7. The proportion of symptomatic intracranial hemorrhage

    Symptomatic intracranial hemorrhage within 24 hours (as defined by Heidelberg criteria)

    Time frame: 24 hours

  8. The proportion of all-cause mortality

    All-cause mortality at 90 days and 1 year

    Time frame: 90 days and 1 year

  9. The proportion of systematic bleeding

    Moderate or severe systemic bleeding is defined according to the criteria established in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial

    Time frame: 90 days

  10. The proportion of serious adverse events (SAEs)

    serious adverse events within 90 days

    Time frame: 90 days

Other outcomes

  1. The proportion of successful recanalization

    The proportion of successful recanalization(eTICI 2b50-3) following EVT

    Time frame: immediately after the intervention

  2. The proportion of improvement on reperfusion at 24 hours after randomization

    Improvement on reperfusion is defined as \>90% reduction in Tmax \> 6s lesion volume

    Time frame: 24 hours

  3. The proportion of complete recanalization at 24 hours after randomization

    Complete recanalization is defined as an Arterial Occlusion Lesion scale \[AOL\] score of 3 (scale range, 0 \[no recanalization\] to 3 \[complete recanalization\]).

    Time frame: 24 hours

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Sep 2027, 19 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 19 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Jan 7, 2026
StartActual
Feb 8, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2028
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07323368
Responsible party
Yunyun Xiong (Professor, Beijing Tiantan Hospital) — Principal investigator
First posted
Jan 7, 2026
Start date
Feb 8, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Feb 10, 2026

Study contacts

Yunyun Xiong, professor
Contact
xiongyunyun@bjtth.org
86-10-59978350
Yunyun Xiong, professor
principal investigator · Beijing Tiantan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion